HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts.

Abstract
The FDA-approved BRAF inhibitor vemurafenib achieves outstanding clinical response rates in patients with melanoma, but early resistance is common. Understanding the pathologic mechanisms of drug resistance and identification of effective therapeutic alternatives are key scientific challenges in the melanoma setting. Using proteomic techniques, including shotgun analysis and 2D-gel electrophoresis, we identified a comprehensive signature of the vemurafenib-resistant M24met in comparison with the vemurafenib-sensitive A375 melanoma cell line. The resistant cells were characterized by loss of differentiation, induction of transformation, enhanced expression of the lysosomal compartment, increased potential for metastasis, migration, adherence and Ca2(+) ion binding, enhanced expression of the MAPK pathway and extracellular matrix proteins, and epithelial-mesenchymal transformation. The main features were verified by shotgun analysis with QEXACTIVE orbitrap MS, electron microscopy, lysosomal staining, Western blotting, and adherence assay in a VM-1 melanoma cell line with acquired vemurafenib resistance. On the basis of the resistance profile, we were able to successfully predict that a novel resveratrol-derived COX-2 inhibitor, M8, would be active against the vemurafenib-resistant but not the vemurafenib-sensitive melanoma cells. Using high-throughput methods for cell line and drug characterization may thus offer a new way to identify key features of vemurafenib resistance, facilitating the design of effective rational therapeutic alternatives.
AuthorsVerena Paulitschke, Walter Berger, Philipp Paulitschke, Elisabeth Hofstätter, Bernhard Knapp, Ruth Dingelmaier-Hovorka, Dagmar Födinger, Walter Jäger, Thomas Szekeres, Anastasia Meshcheryakova, Andrea Bileck, Christine Pirker, Hubert Pehamberger, Christopher Gerner, Rainer Kunstfeld
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 14 Issue 3 Pg. 757-68 (Mar 2015) ISSN: 1538-8514 [Electronic] United States
PMID25612618 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright©2015 American Association for Cancer Research.
Chemical References
  • Cyclooxygenase 2 Inhibitors
  • Indoles
  • Proteome
  • Sulfonamides
  • Vemurafenib
  • Proto-Oncogene Proteins B-raf
Topics
  • Cell Differentiation (drug effects, genetics)
  • Cell Line, Tumor
  • Cell Transformation, Neoplastic (drug effects, genetics)
  • Cyclooxygenase 2 Inhibitors (pharmacology, therapeutic use)
  • Drug Resistance, Neoplasm (genetics)
  • Epithelial-Mesenchymal Transition (drug effects, genetics)
  • Female
  • Humans
  • Indoles (pharmacology, therapeutic use)
  • MAP Kinase Signaling System (drug effects, genetics)
  • Melanoma (drug therapy, genetics)
  • Proteome (genetics)
  • Proteomics (methods)
  • Proto-Oncogene Proteins B-raf (antagonists & inhibitors)
  • Sulfonamides (pharmacology, therapeutic use)
  • Vemurafenib
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: